Quarterly ResultMay 7, 2026, 07:33 AM
Ascendis Pharma Q1 Revenue €247M; Sells PRV for $187.5M
AI Summary
Ascendis Pharma A/S announced strong financial results for Q1 2026, with total revenue reaching €247 million, a significant increase from the prior year. The company also entered an agreement to sell its Rare Pediatric Disease Priority Review Voucher for $187.5 million. Key product YORVIPATH generated €197 million in revenue, while YUVIWEL received FDA approval and saw over 60 patient enrollments since its April U.S. launch. However, the company decided to discontinue internal development of its oncology program, TransCon IL-2 β/γ.
Key Highlights
- Ascendis Pharma Q1 2026 total revenue was €247 million, up from €101 million in Q1 2025.
- Company entered agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million.
- YORVIPATH revenue for Q1 2026 totaled €197 million, with over 1,000 new U.S. patient enrollments.
- SKYTROFA revenue for Q1 2026 totaled €44 million.
- YUVIWEL received U.S. FDA accelerated approval and had over 60 patient enrollments since April launch.
- Q1 2026 net profit was €629 million (€9.75 diluted EPS), including €679 million deferred tax asset recognition.
- Non-IFRS operating profit for Q1 2026 was €55 million, compared to a €79 million loss in Q1 2025.
- Ascendis Pharma discontinued internal development of TransCon IL-2 β/γ in Oncology.